A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma

A Study Protocol

Nobukazu Fujimoto, Keisuke Aoe, Toshiyuki Kozuki, Isao Oze, Katsuya Kato, Takumi Kishimoto, Katsuyuki Hotta

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: The purpose of this study is to assess the efficacy and safety of combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma (MPM). Patients and Methods: Patients with untreated, advanced, or metastatic MPM who meet the inclusion and exclusion criteria will be included. A total of 18 patients will be enrolled from 4 Japanese institutions within 1 year. Combination chemotherapy with cisplatin (75 mg/m2), pemetrexed (500 mg/m2), and nivolumab (360 mg/person) is administered every 3 weeks for a total of 4 to 6 cycles. Then, maintenance therapy with nivolumab will be administered until disease progression, unacceptable toxicities, or the patient's condition meets the withdrawal criteria. The primary end point is the centrally reviewed overall response rate. The secondary end points include the disease control rate, overall survival, progression-free survival, and adverse events. Conclusion: This phase II trial evaluating first-line combination chemotherapy for unresectable MPM commenced in January 2018. This is the first prospective trial to evaluate the effect of an anti-programmed death-1 antibody combined with cisplatin and pemetrexed for unresectable MPM.

Original languageEnglish
JournalClinical Lung Cancer
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Pemetrexed
Combination Drug Therapy
Cisplatin
Disease-Free Survival
Disease Progression
Survival Rate
Safety
Malignant Mesothelioma
nivolumab
Antibodies

Keywords

  • Asbestos
  • Immune checkpoint inhibitor
  • Maintenance
  • Programmed death-1
  • Prospective study

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma : A Study Protocol. / Fujimoto, Nobukazu; Aoe, Keisuke; Kozuki, Toshiyuki; Oze, Isao; Kato, Katsuya; Kishimoto, Takumi; Hotta, Katsuyuki.

In: Clinical Lung Cancer, 01.01.2018.

Research output: Contribution to journalArticle

@article{9e0309d8bd344c98b94ba1d450b39d22,
title = "A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol",
abstract = "Background: The purpose of this study is to assess the efficacy and safety of combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma (MPM). Patients and Methods: Patients with untreated, advanced, or metastatic MPM who meet the inclusion and exclusion criteria will be included. A total of 18 patients will be enrolled from 4 Japanese institutions within 1 year. Combination chemotherapy with cisplatin (75 mg/m2), pemetrexed (500 mg/m2), and nivolumab (360 mg/person) is administered every 3 weeks for a total of 4 to 6 cycles. Then, maintenance therapy with nivolumab will be administered until disease progression, unacceptable toxicities, or the patient's condition meets the withdrawal criteria. The primary end point is the centrally reviewed overall response rate. The secondary end points include the disease control rate, overall survival, progression-free survival, and adverse events. Conclusion: This phase II trial evaluating first-line combination chemotherapy for unresectable MPM commenced in January 2018. This is the first prospective trial to evaluate the effect of an anti-programmed death-1 antibody combined with cisplatin and pemetrexed for unresectable MPM.",
keywords = "Asbestos, Immune checkpoint inhibitor, Maintenance, Programmed death-1, Prospective study",
author = "Nobukazu Fujimoto and Keisuke Aoe and Toshiyuki Kozuki and Isao Oze and Katsuya Kato and Takumi Kishimoto and Katsuyuki Hotta",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.cllc.2018.05.001",
language = "English",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",

}

TY - JOUR

T1 - A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma

T2 - A Study Protocol

AU - Fujimoto, Nobukazu

AU - Aoe, Keisuke

AU - Kozuki, Toshiyuki

AU - Oze, Isao

AU - Kato, Katsuya

AU - Kishimoto, Takumi

AU - Hotta, Katsuyuki

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: The purpose of this study is to assess the efficacy and safety of combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma (MPM). Patients and Methods: Patients with untreated, advanced, or metastatic MPM who meet the inclusion and exclusion criteria will be included. A total of 18 patients will be enrolled from 4 Japanese institutions within 1 year. Combination chemotherapy with cisplatin (75 mg/m2), pemetrexed (500 mg/m2), and nivolumab (360 mg/person) is administered every 3 weeks for a total of 4 to 6 cycles. Then, maintenance therapy with nivolumab will be administered until disease progression, unacceptable toxicities, or the patient's condition meets the withdrawal criteria. The primary end point is the centrally reviewed overall response rate. The secondary end points include the disease control rate, overall survival, progression-free survival, and adverse events. Conclusion: This phase II trial evaluating first-line combination chemotherapy for unresectable MPM commenced in January 2018. This is the first prospective trial to evaluate the effect of an anti-programmed death-1 antibody combined with cisplatin and pemetrexed for unresectable MPM.

AB - Background: The purpose of this study is to assess the efficacy and safety of combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma (MPM). Patients and Methods: Patients with untreated, advanced, or metastatic MPM who meet the inclusion and exclusion criteria will be included. A total of 18 patients will be enrolled from 4 Japanese institutions within 1 year. Combination chemotherapy with cisplatin (75 mg/m2), pemetrexed (500 mg/m2), and nivolumab (360 mg/person) is administered every 3 weeks for a total of 4 to 6 cycles. Then, maintenance therapy with nivolumab will be administered until disease progression, unacceptable toxicities, or the patient's condition meets the withdrawal criteria. The primary end point is the centrally reviewed overall response rate. The secondary end points include the disease control rate, overall survival, progression-free survival, and adverse events. Conclusion: This phase II trial evaluating first-line combination chemotherapy for unresectable MPM commenced in January 2018. This is the first prospective trial to evaluate the effect of an anti-programmed death-1 antibody combined with cisplatin and pemetrexed for unresectable MPM.

KW - Asbestos

KW - Immune checkpoint inhibitor

KW - Maintenance

KW - Programmed death-1

KW - Prospective study

UR - http://www.scopus.com/inward/record.url?scp=85047492553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047492553&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2018.05.001

DO - 10.1016/j.cllc.2018.05.001

M3 - Article

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

ER -